These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 11694861

  • 1. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z, Seres I, Harangi M, Kovács P, Kakuk G, Paragh G.
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [Abstract] [Full Text] [Related]

  • 2. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD.
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [Abstract] [Full Text] [Related]

  • 3. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS.
    Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
    [Abstract] [Full Text] [Related]

  • 4. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Dec; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 5. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
    Juretić D, Motejlkova A, Kunović B, Rekić B, Flegar-Mestrić Z, Vujić L, Mesić R, Lukac-Bajalo J, Simeon-Rudolf V.
    Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
    [Abstract] [Full Text] [Related]

  • 6. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 7. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD.
    Am J Cardiol; 2005 Nov 01; 96(9):1266-72. PubMed ID: 16253595
    [Abstract] [Full Text] [Related]

  • 8. Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
    Hsu HC, Lee YT, Yeh HT, Chen MF.
    J Lab Clin Med; 2001 Jun 01; 137(6):414-21. PubMed ID: 11385362
    [Abstract] [Full Text] [Related]

  • 9. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P.
    Curr Med Res Opin; 2004 Aug 01; 20(8):1321-7. PubMed ID: 15324535
    [Abstract] [Full Text] [Related]

  • 10. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP, de Vries R, Sluiter WJ, Voorbij HA.
    Clin Endocrinol (Oxf); 2009 Feb 01; 70(2):221-6. PubMed ID: 18505467
    [Abstract] [Full Text] [Related]

  • 11. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Tremoli E, Maderna P, Colli S, Zoppi F.
    J Lab Clin Med; 1987 Sep 01; 110(3):279-86. PubMed ID: 3475394
    [Abstract] [Full Text] [Related]

  • 12. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
    Dullaart RP, de Vries R, Voorbij HA, Sluiter WJ, van Tol A.
    Eur J Clin Invest; 2009 Mar 01; 39(3):200-3. PubMed ID: 19260949
    [Abstract] [Full Text] [Related]

  • 13. Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus.
    Sonoki K, Iwase M, Sasaki N, Ohdo S, Higuchi S, Matsuyama N, Iida M.
    Diabetes Res Clin Pract; 2009 Nov 01; 86(2):117-23. PubMed ID: 19748147
    [Abstract] [Full Text] [Related]

  • 14. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes.
    Wallace AJ, Sutherland WH, Mann JI, Williams SM.
    Eur J Clin Nutr; 2001 Nov 01; 55(11):951-8. PubMed ID: 11641743
    [Abstract] [Full Text] [Related]

  • 15. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
    Koskinen P, Kovanen PT, Tuomilehto J, Manninen V.
    Arch Intern Med; 1992 Jan 01; 152(1):90-6. PubMed ID: 1728934
    [Abstract] [Full Text] [Related]

  • 16. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women.
    Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM.
    Metabolism; 2001 Mar 01; 50(3):319-24. PubMed ID: 11230785
    [Abstract] [Full Text] [Related]

  • 17. Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
    Fasching P, Rohac M, Liener K, Schneider B, Nowotny P, Waldhäusl W.
    Horm Metab Res; 1996 May 01; 28(5):230-6. PubMed ID: 8738112
    [Abstract] [Full Text] [Related]

  • 18. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
    Yesilbursa D, Serdar A, Saltan Y, Serdar Z, Heper Y, Guclu S, Cordan J.
    Kardiol Pol; 2005 Jun 01; 62(6):526-30. PubMed ID: 16123850
    [Abstract] [Full Text] [Related]

  • 19. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 01; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 20. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
    Turay J, Grniaková V, Valka J.
    Drugs Exp Clin Res; 2000 Nov 01; 26(3):83-8. PubMed ID: 10941600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.